Medifast, Inc. (MED) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Medifast, Inc. operates a single reportable segment, OPTA VIA, focused on a coach-guided metabolic health and wellness system. The company is executing a strategic transformation announced in October 2025 to address metabolic dysfunction through science-backed products and coaching, aiming to complement the growing market for GLP-1 medications.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $76.0 million | $115.7 million |
| Gross Profit | $51.8 million (68.1% margin) | $84.2 million (72.8% margin) |
| Operating Loss | $(3.3) million | $(1.3) million |
| Net Loss | $(2.1) million | $(0.8) million |
| Loss Per Share (Diluted) | $(0.19) | $(0.07) |
| Cash & Cash Equivalents | $71.5 million | $91.7 million |
| Total Investments | $97.4 million | $78.0 million |
| Working Capital | $160.4 million | $158.7 million |
| Operating Cash Flow | $0.3 million | $3.4 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 34.3% year-over-year, primarily driven by a reduction in active earning coaches from 25,400 in Q1 2025 to 14,000 in Q1 2026. Management attributes this to broader market challenges and the rapid adoption of GLP-1 weight loss medications.
- Cost Structure: Cost of sales decreased 22.9%, and SG&A expenses decreased 35.6%. The SG&A reduction included a one-time $2.2 million gain on the sale of the Maryland Distribution Center, lower coach compensation due to volume, and reduced marketing spend.
- Profitability: Operating loss widened to $3.3 million from $1.3 million due to the significant revenue drop and loss of leverage on fixed costs, despite expense reductions.
- Investment Activity: The company increased its investment portfolio by approximately $19.4 million, shifting funds from cash equivalents to debt securities (government and corporate bonds).
Outlook, Risks, and Management Commentary
- Strategic Focus: Management expects the number of active earning coaches to continue declining in 2026 as the company transitions to a metabolic health focus. The strategy relies on improving coach productivity and expanding the network with a new "flywheel effect" model.
- Product Innovation: The company plans to launch updated product lines with next-generation ingredients for metabolic enhancement later in 2026.
- Competition: GLP-1 medications are identified as a major competitive threat, though management views them as complementary to their lifestyle and coaching model.
- Risks: Key risks include macroeconomic volatility (inflation, tariffs), continued decline in coach numbers, and the potential for unfavorable resolution of legal proceedings, though no material adverse effects are currently anticipated.
- Tax Provision: The effective tax rate was negative 9.3% due to a full valuation allowance against deferred tax assets, resulting in a provision based primarily on discrete state tax items.
Investor Verification Checklist
- Coach Network Trend: Verify the sustainability of the 14,000 active coach count and the effectiveness of new initiatives (e.g., EDGE program) in halting the decline.
- Revenue Per Coach: Monitor if the increase in revenue per active coach ($5,432 vs. $4,556) can offset the shrinking network size.
- Cash Burn vs. Liquidity: Assess the impact of negative operating cash flow ($0.3M) against the strong liquidity position ($168.9M in cash and investments).
- Fixed Cost Leverage: Evaluate management's ability to further reduce fixed costs to match the lower revenue base and improve gross margins.
- Product Launch Timeline: Confirm the timing and market reception of the upcoming metabolic health product innovations.